Longeveron (NASDAQ:LGVN) Issues Earnings Results

Longeveron (NASDAQ:LGVN) announced its quarterly earnings results on Wednesday. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19), FiscalAI reports. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 237.79%.

Here are the key takeaways from Longeveron’s conference call:

• Longeveron said it raised new capital from several life sciences investors and is shifting to a more capital-efficient, asset-light model that emphasizes partnering to maximize shareholder value.
• The company reiterated that the most important near-term catalyst is ELPIS II top-line data for HLHS, expected in August 2026, and it plans to engage the FDA quickly after the readout.
• After a recent Type C meeting, the FDA said the current primary endpoint in ELPIS II is not appropriate for demonstrating efficacy and no new primary endpoint can be agreed to while the trial is ongoing.
• Management remains optimistic that ELPIS II results, together with other evidence and a sponsor SAP, could still support a future BLA, and the FDA said it is willing to meet again once the study is complete.
• Cash and cash equivalents were $15.8 million at quarter-end, and the company said this should fund operations into Q4 2026 based on its current budget and forecast.

Longeveron Price Performance

Shares of NASDAQ:LGVN traded down $0.05 during trading on Friday, reaching $0.65. The stock had a trading volume of 276,637 shares, compared to its average volume of 3,822,156. Longeveron has a 52 week low of $0.48 and a 52 week high of $1.80. The business’s 50-day moving average price is $0.93 and its 200 day moving average price is $0.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.33 and a quick ratio of 1.33. The stock has a market capitalization of $15.22 million, a PE ratio of -0.59 and a beta of -0.31.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new position in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LGVN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research note on Monday. Finally, HC Wainwright cut their target price on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.50.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.